Literature DB >> 11889061

Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants.

R C Fitzgerald1, B A Onwuegbusi, M Bajaj-Elliott, I T Saeed, W R Burnham, M J G Farthing.   

Abstract

BACKGROUND AND AIMS: Approximately 10% of adults experience gastro-oesophageal reflux symptoms with a variable oesophageal response. A total of 60% have no endoscopic abnormality, 30% have oesophagitis, and 10% have Barrett's oesophagus. We investigated whether the inflammatory cell infiltrate and cytokine profiles of these clinical phenotypes merely vary in severity or are fundamentally different.
METHODS: Patients with reflux symptoms and a normal oesophagus (n=18), oesophagitis (n=26), and Barrett's oesophagus (n=22 newly diagnosed, n=28 surveillance) were recruited. Endoscopic and histopathological degrees of inflammation were scored. Cytokine expression was determined by competitive reverse transcriptase-polymerase chain reaction and immunohistochemistry.
RESULTS: In oesophagitis, endoscopic and histopathological grades of inflammation correlated highly. mRNA expression of proinflammatory interleukin (IL)-1beta, IL-8, and interferon gamma (IFN-gamma) were increased 3-10-fold compared with non-inflamed squamous or Barrett's oesophageal samples. There was a modest increase in anti-inflammatory IL-10 but no increase in IL-4. In Barrett's oesophagus, 29/50 had no endoscopic evidence of inflammation and histopathological inflammation was mild in 17/50 and moderate in 24/50, independent of acid suppressants. Expression of IL-1beta, IL-8, and IFN-gamma was similar to non-inflamed squamous mucosa. IL-10 was increased 1.6-fold similar to oesophagitis. IL-4 was increased fourfold, with 100-fold increase in IL-4/T cell receptor expression, compared with squamous oesophagus or oesophagitis.
CONCLUSIONS: Barrett's oesophagus is characterised by a distinct Th-2 predominant cytokine profile compared with the proinflammatory nature of oesophagitis. The specific oesophageal immune responses may influence disease development and progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889061      PMCID: PMC1773186          DOI: 10.1136/gut.50.4.451

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  58 in total

1.  Histologic abnormalities in reflux esophagitis.

Authors:  J Behar; D Sheahan
Journal:  Arch Pathol       Date:  1975-07

2.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer.

Authors:  E M El-Omar; M Carrington; W H Chow; K E McColl; J H Bream; H A Young; J Herrera; J Lissowska; C C Yuan; N Rothman; G Lanyon; M Martin; J F Fraumeni; C S Rabkin
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

3.  Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion.

Authors:  S A McClave; H W Boyce; M R Gottfried
Journal:  Gastrointest Endosc       Date:  1987-12       Impact factor: 9.427

4.  Histological consequences of gastroesophageal reflux in man.

Authors:  F Ismail-Beigi; P F Horton; C E Pope
Journal:  Gastroenterology       Date:  1970-02       Impact factor: 22.682

5.  Health-related quality of life in primary care patients with gastroesophageal reflux disease.

Authors:  B Kaplan-Machlis; G E Spiegler; D A Revicki
Journal:  Ann Pharmacother       Date:  1999-10       Impact factor: 3.154

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

7.  Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.

Authors:  C Winters; T J Spurling; S J Chobanian; D J Curtis; R L Esposito; J F Hacker; D A Johnson; D F Cruess; J D Cotelingam; M S Gurney
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

8.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Authors:  R H Riddell; H Goldman; D F Ransohoff; H D Appelman; C M Fenoglio; R C Haggitt; C Ahren; P Correa; S R Hamilton; B C Morson
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

9.  Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  J Jankowski; D Hopwood; K G Wormsley
Journal:  Scand J Gastroenterol       Date:  1992       Impact factor: 2.423

10.  Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis.

Authors:  H S Winter; J L Madara; R J Stafford; R J Grand; J E Quinlan; H Goldman
Journal:  Gastroenterology       Date:  1982-10       Impact factor: 22.682

View more
  92 in total

1.  Increased expression of VEGF, COX-2, and Ki-67 in Barrett's esophagus: does the length matter?

Authors:  Evanthia Zampeli; George Karamanolis; George Morfopoulos; Elias Xirouchakis; Vasiliki Kalampoki; Spyros Michopoulos; Sotiria Savva; Vasilios Tzias; Irene Zouboulis-Vafiadis; Dimitrios Kamberoglou; Spiros D Ladas
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

Review 2.  Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.

Authors:  Arne Kandulski; Peter Malfertheiner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-22       Impact factor: 46.802

Review 3.  Barrett esophagus: an update.

Authors:  Rami J Badreddine; Kenneth K Wang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 46.802

4.  CDX1 is an important molecular mediator of Barrett's metaplasia.

Authors:  N A C S Wong; J Wilding; S Bartlett; Y Liu; B F Warren; J Piris; N Maynard; R Marshall; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-13       Impact factor: 11.205

Review 5.  Gastro-oesophageal reflux disease.

Authors:  Mark Fox; Ian Forgacs
Journal:  BMJ       Date:  2006-01-14

6.  Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis.

Authors:  Daniel J Mulder; Aman Pooni; Nanette Mak; David J Hurlbut; Sameh Basta; Christopher J Justinich
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

7.  In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-κB and activator protein-1.

Authors:  Xiaofang Huo; Xi Zhang; Chunhua Yu; Qiuyang Zhang; Edaire Cheng; David H Wang; Thai H Pham; Stuart J Spechler; Rhonda F Souza
Journal:  Gut       Date:  2013-09-18       Impact factor: 23.059

8.  Inflammatory gradient in Barrett's oesophagus: implications for disease complications.

Authors:  R C Fitzgerald; S Abdalla; B A Onwuegbusi; P Sirieix; I T Saeed; W R Burnham; M J G Farthing
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.

Authors:  Amel Saadi; Nicholas B Shannon; Pierre Lao-Sirieix; Maria O'Donovan; Elaine Walker; Nicholas J Clemons; James S Hardwick; Chunsheng Zhang; Madhumita Das; Vicki Save; Marco Novelli; Frances Balkwill; Rebecca C Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

Review 10.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.